EP1450629A1 - Formulation solide et stable contenant au moins un compose de type creatine/acide citrique et au moins un glucide ou leurs hydrates, son procede de production et son utilisation - Google Patents

Formulation solide et stable contenant au moins un compose de type creatine/acide citrique et au moins un glucide ou leurs hydrates, son procede de production et son utilisation

Info

Publication number
EP1450629A1
EP1450629A1 EP02785417A EP02785417A EP1450629A1 EP 1450629 A1 EP1450629 A1 EP 1450629A1 EP 02785417 A EP02785417 A EP 02785417A EP 02785417 A EP02785417 A EP 02785417A EP 1450629 A1 EP1450629 A1 EP 1450629A1
Authority
EP
European Patent Office
Prior art keywords
creatine
citric acid
acid composition
carbohydrate
solid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP02785417A
Other languages
German (de)
English (en)
Inventor
Martin Purpura
Ivo Pischel
Ralf JÄGER
Günter Ortenburger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cargill Texturizing Solutions Deutschland GmbH and Co KG
Original Assignee
Bioghurt Biogarde GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioghurt Biogarde GmbH and Co KG filed Critical Bioghurt Biogarde GmbH and Co KG
Publication of EP1450629A1 publication Critical patent/EP1450629A1/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to a formulation which contains one or more solid and stable creatine / citric acid compounds and one or more carbohydrates or their hydrates, a process for their preparation and their use.
  • Creatine salts are known in a wide variety of forms and contain the physiologically harmless creatine cation of the formula (I)
  • Creatine is not only an endogenous substance and a valuable nutritional supplement, but also has valuable therapeutic properties. Creatine has been known as a muscle substance for over 100 years, and it serves as a source of energy for the muscle. A number of scientific studies have shown that taking creatine can lead to an increase in muscle mass and muscle performance. There is also scientific evidence that the pancreas releases more insulin under the influence of creatine. Insulin promotes the absorption of glucose and amino acids in the muscle cell and stimulates protein synthesis. Insulin also reduces the rate of protein breakdown. Citric acid is a tricarboxylic acid that is known to be common in the plant kingdom as well as in many animal tissues and body fluids. Citric acid is one of the series of prominent compounds that are involved in the physiological oxidation of fats, proteins and carbohydrates to carbon dioxide and water (see, inter alia, tricarboxylic acid cycle).
  • Citric acid which was first isolated from lime juice by the Swedish chemist Karl Wilhelm Scheele in 1784, is currently produced biotechnologically by fermentation of cane sugar or molasses by the Aspergillus niger mold. Citric acid is used in its natural form or as a food additive E 330 in the packaging of food, but also in baking powders, lemonade and generally for acidification and as a flavoring. Citric acid is also used to increase the stability of foods or other organic substances.
  • the pure, anhydrous citric acid mostly forms colorless, rhombic crystals with a slightly acidic taste.
  • U.S. Patent 5,973,199 discloses, inter alia, Isolated, water-soluble salts of creatine and citric acid are known, which have a melting point of 1 1 2 to 1 1 4 ° C.
  • This creatine citrate is produced by suspending citric acid monohydrate in ethyl acetate, then adding creatine monohydrate and then mixing the mixture for 4 hours at 25 ° C. This gives a product which contains about 90% of creatine citrate with a melting point between 11 and 14 ° C. and varying proportions of solvents.
  • di- and tricreatine citrates (US Pat. No. 6,21,1407), the melting points of which should be 146 ° C. or 1,54 ° C. and which have a creatine content of 57.7 or 67.2% by weight. -% exhibit. Information about however, the structure of such salts cannot be found in this document.
  • Effervescent formulations which contain creatine citrate as a 1: 1 salt or physical mixtures of creatine and citric acid are known from US Pat. No. 5,925,378.
  • creatine salts such as The creatine pyruvates and ascorbates as well as the citrates have valuable physiological, therapeutic and dietary properties.
  • Most of the known creatine salts are used, for example, to increase endurance and strength in sports, to reduce weight and body fat, and as a protective substance for body cells and tissues, in particular cardiovascular, hepatic, nephrotic, peritoneal and neuronal tissue, as a substance for inhibition radical formation and as a radical scavenger substance in body cells and tissues (also synovial tissue), furthermore in the health sector and as a food supplement.
  • creatine pyruvates Typical of the physical properties of many creatine salts are the creatine pyruvates, which as stable substances are stable compounds at temperatures below 40 ° C. However, if creatine pyruvate is exposed to temperatures above 40 ° C or if formulations containing creatine pyruvate are produced with the addition of certain non-stabilizing substances, a rapid disintegration of the creatine pyruvate can be observed.
  • the storage stability of the creatine pyruvates is usually not very pronounced, especially at higher temperatures, which is probably also due to the fact that, for example, the pyruvates are unstable 2-oxocarboxylic acid salts and more the most of decompose known salts of creatine easily to form creatinine. Since creatine is also present as an inner salt and is only a weak base, the storage stability is negatively influenced, especially over a longer period. In particular, combinations of creatine compounds, such as, for example, citrates with compounds that tend to be unstable, lead to quality losses for these reasons.
  • WO 98/28263 discloses pyruvates in the form of storage-stable creatine compounds which, in addition to pharmaceutical formulation auxiliaries and others, are available in physiologically compatible compositions. can also be combined with carbohydrates such as glucose, dextrose and maltose.
  • Formulations containing creatine consisting of a neurotransmitter, lipoic acid and optionally L-camitin, coenzyme Q and other physiologically active additives, such as e.g. Sugars, describes DE-OS 1 98 30 768, which formulations can contain, in particular, creatine pyruvate and, inter alia, should also be stable in storage.
  • DE-OS 1 98 36 450 discloses stable pyruvic acid (salts) - containing formulations for animal nutrition which, in addition to three further component groups, also contain physiologically valuable additives, such as carbohydrates.
  • Organic acids such as citric acid and aminocarboxylic acids such as creatine are proposed as further components.
  • the preferred pyruvic acid salt is the creatine pyruvate.
  • Combinations of creatine salts with carbohydrates are now known from the last four documents, and formulations are also described which may contain creatine, citric acid and carbohydrates. However, there is no indication that compositions consisting of creatine and citric acid can improve storage stability and other properties.
  • compositions (s) in an easily metered form in which the disadvantages of the prior art are at least partially eliminated.
  • creatine / citric acid composition when formulated with carbohydrates, become extremely temperature- and storage-stable even when other unstable and / or unstabilizing compounds are added.
  • This increased storage stability even at elevated temperatures of e.g. 30 ° C and in particular> 35 ° C even for a long period of time is shown by a reduced formation of creatinine as a degradation product.
  • the formulations according to the invention preferably have a creatinine content of 500 500 ppm, particularly preferably of ⁇ 350 ppm.
  • the formulation according to the invention thus enables the compositions in question, consisting of creatine and citric acid, to be stored for a significantly longer time, as well as an increased resilience with regard to temperature and duration, both during processing and storage, which makes them accessible, for example, to new production and / or formulation processes.
  • such formulations have proven to be particularly suitable, the components of which are creatine / citric acid composition (s) and carbohydrate (s) in a weight ratio of 1: 0.01 to 0.5 and very particularly preferably in a weight ratio of about 1: 0 , 1 are present.
  • Preferred embodiments of the claimed formulations have a water content of up to 30% by weight.
  • Creatine components which have proven particularly suitable are those which, as creatine / citric acid composition (s), contain physiologically tolerable salts, deposits and complexes in a molar ratio of creatine to citric acid of 1.0 to 3.0: 1.0.
  • creatine / citric acid compounds that are unstable to external influences.
  • their combinations with stable creatine / citric acid compositions are also encompassed by the invention.
  • any carbohydrates for example all polyhydroxy aldehydes (aldoses) and polyhydroxy ketones (ketoses) and their derivatives, can be used to stabilize the formulations.
  • aldo- and ketohexoses and the oligo- or polysaccharides derived therefrom and their O-glycosidic derivatives have proven particularly useful.
  • monosaccharides such as glucose, fructose, ribose and sorbitol, and / or cyclic and open-chain oligohexoses with 2 to 10 monomer units, such as sucrose, lactose and maltose, but also polysaccharides with 1 1 to 10 6 monomer units, such as.
  • B. inulin, arabino-galactan, maltodextrins, starch, chitosan and glycogen are preferred. It is important that any mixture of carbohydrates can be used.
  • the present invention also takes into account formulations which, in addition to the components essential to the invention, additionally contain other creatine-containing compositions, in particular creatine salts, such as creatine pyruvates and ascorbates.
  • creatine salts such as creatine pyruvates and ascorbates.
  • proteins e.g. Collagen or whey powder
  • suitable acids such as, for example, ascorbic acid
  • the carbohydrate (s) are in the form of solutions, suspensions or as a solid substance with the creatine / citric acid composition in the temperature range from -20 to 120 ° C. and preferably implemented between 10 and 90 ° C., whereupon the solution obtained is optionally finally freed from the liquid phase, which is preferably carried out by solid / liquid separation, distillation, evaporation and / or concentration in each case in vacuo, spray drying or freeze drying or by any other suitable separation method.
  • a mixture consisting of the acidic creatine / citric acid component or its solution and the solid carbohydrate component is subjected to a thermal treatment, a treatment with ultrasound and / or a microwave in the temperature range from -20 to 120 ° C. which can also be done in a vacuum and leads to the formation of homogeneous formulations. All of these reactions can be carried out in the presence of a solvent or diluent or also solvent-free. All common solvents, such as water, alcohols, ethers, ketones, esters, organic acids, aliphatic and aromatic hydrocarbons, have proven to be suitable solvents or diluents for the production of the aggregates claimed.
  • the desired formulations can also be obtained simply by mixing the components dry.
  • the carbohydrate component can be used to form the formulation in anhydrous form, as a hydrate or as a moist product.
  • the acidic creatine salt component can also be used in anhydrous form, in aqueous solution or dissolved in one of the alcoholic or organic solvents or diluents already mentioned. All of the claimed implementation variants can be carried out in the known process engineering apparatuses, such as in kneaders, mixers, paddle dryers, stirred tanks and spray dryers.
  • the creatine / citric acid composition (s) and carbohydrate-containing formulations according to the invention are thus obtained in high yield and purity without further necessary cleaning steps.
  • the present invention thus provides that either both starting components are used in solid or in liquid form or that one component is solid and the other is liquid. It should only be noted that for the formulations according to the invention the creatine / citric acid component and the carbohydrate component are always used within the claimed weight ratios.
  • the formulations according to the invention are used for pharmaceutical purposes or in Food industry, e.g. for increasing endurance and strength in sports, for reducing weight and body fat as well as a protective substance for body cells and tissues, especially cardiovascular, hepatic, ophthalmic, nephrotic and neuronal and transplant tissues, and as a substance for inhibiting radical formation and as Radical scavenger substance in body cells and tissues (also synovial tissue), in the health sector, in particular in the treatment of obesity and obesity, in the case of skin disorders, for wound healing and for lowering blood pressure, as well as in mental disorders in women, which are mainly caused by changes in the female sex hormone balance, such as Symptoms of premenstrual syndrome (PMS), dysmenorrhea, menopause, weather sensitivity, migraines, tension headache, insomnia and disturbed mood, and as a nutritional supplement.
  • PMS Symptoms of premenstrual syndrome
  • dysmenorrhea menopause
  • weather sensitivity migraines
  • migraines tension headache
  • formulations according to the invention can be administered in the form of tablets, powders, dragees, capsules, drinks and jellies and in particular as effervescent tablets and effervescent powder, this series being able to be extended as desired.
  • the present invention thus represents an important advance in the use of creatine / citric acid compositions in the therapeutic and dietetic field and in sports medicine. Because of the prior art, it was not to be expected that solid and storage-stable creatine / citric acid composition (s ) and carbohydrate-containing formulations are accessible with simple methods and lead to easy-to-dose products. In addition, it has been shown that the creatine / citric acid compositions do not undergo any condensation and decomposition reactions, but at most only very slight, when preparing the formulations. Of Furthermore, the claimed creatine / citric acid composition (s) and carbohydrate-containing formulations can be produced without subsequent work-up. Aqueous solutions containing the creatine component or solvent can also be used, in which case formulations with defined crystal water contents are obtained.
  • the present invention in particular with the production variants also claimed, does not include mere mixtures of the components of the invention, creatine / citric acid composition (s) and carbohydrate (s), as are already well known from the prior art, but that it is the formulations claimed are actual physical or chemical reaction products.
  • a creatine-citric acid compound (3: 1) (KC) as pure substance and mixtures of this compound (3: 1) with 1, 5 and 10 wt .-% addition of a carbohydrate (KH) were stored at 60 ° C for 28 days and then the contents of the creatine decomposition product creatinine determined.
  • the starting data for the reference substance KC which is stable when cooled to room temperature (RT), with a creatine content of 67.1% by weight and a creatinine content of ⁇ 67 ppm (detection limit) serve as a comparison.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des formulations solides et stables contenant au moins un composé de type créatine/acide citrique et au moins un glucide ou leurs hydrates, et présentant un rapport pondéral entre le(s) composé(s) de type créatine/acide citrique et le(s) glucide(s) compris entre 1:0,01 et 1,0. En principe, tous les polyhydroxyaldéhydes et toutes les polyhydroxycétones conviennent en tant que composants glucides pouvant, sous forme anhydre, être utilisés en tant qu'hydrates ou produits humides. Le composant créatine est de préférence utilisé sous forme anhydre dans une solution aqueuse, alcoolisée ou organique. Théoriquement, le procédé de production de ces formulations consiste de préférence à faire réagir les glucides sous forme de solutions, suspensions ou en tant que substance solide avec le composé de type créatine/acide citrique ou sa solution, à une température comprise entre -20 et 120 DEG C, et finalement, à éventuellement séparer la phase liquide. Ces formulations peuvent également être produites par traitement thermique, un traitement par ultrasons ou micro-ondes de mélanges constitués du composant créatine et de glucides solides, de préférence dans des conditions de vide. Ainsi, ce procédé permet d'obtenir des formulations contenant des composés de type créatine/acide citrique et des glucides, pouvant être employées entre autres pour augmenter l'endurance et la force dans le domaine du sport, à des fins de réduction pondérale et de diminution des graisses corporelles dans le domaine de la santé, pour des troubles de l'humeur chez la femme, en tant que complément alimentaire ainsi que pour l'alimentation animale.
EP02785417A 2001-12-03 2002-11-29 Formulation solide et stable contenant au moins un compose de type creatine/acide citrique et au moins un glucide ou leurs hydrates, son procede de production et son utilisation Ceased EP1450629A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10159244A DE10159244A1 (de) 2001-12-03 2001-12-03 Feste und stabile Kreatin/Citronensäure-Zusammensetzung(en) und Kohlenhydrat(e) bzw. deren Hydrate enthaltende Formulierung, Verfahren zu ihrer Herstellung und deren Verwendung
DE10159244 2001-12-03
PCT/EP2002/013518 WO2003047367A1 (fr) 2001-12-03 2002-11-29 Formulation solide et stable contenant au moins un compose de type creatine/acide citrique et au moins un glucide ou leurs hydrates, son procede de production et son utilisation

Publications (1)

Publication Number Publication Date
EP1450629A1 true EP1450629A1 (fr) 2004-09-01

Family

ID=7707821

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02785417A Ceased EP1450629A1 (fr) 2001-12-03 2002-11-29 Formulation solide et stable contenant au moins un compose de type creatine/acide citrique et au moins un glucide ou leurs hydrates, son procede de production et son utilisation

Country Status (6)

Country Link
US (1) US20050037069A1 (fr)
EP (1) EP1450629A1 (fr)
JP (1) JP2005510579A (fr)
AU (1) AU2002350718A1 (fr)
DE (1) DE10159244A1 (fr)
WO (1) WO2003047367A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080003208A1 (en) * 2006-05-11 2008-01-03 Avicena Froup, Inc. Creatine-ligand compounds and methods of use thereof
US20080197213A1 (en) * 2007-02-20 2008-08-21 Flashinski Stanley J Active material diffuser and method of providing and using same
EP2303040A1 (fr) * 2008-06-06 2011-04-06 PhytoLab GmbH & Co. KG Stimulation synergique de l absorption cellulaire de nutriments ergogènes, tel que la créatine ou la carnitine, avec l estragon
DE102010045366A1 (de) * 2010-09-14 2012-03-15 Ozren König Mittel zur Therapie und vorbeugenden Behandlung von Migräne und Migräne/Cluster- ähnlichen Kopfschmerzen
GB201107308D0 (en) 2011-05-03 2011-06-15 Gorman Edward O Oral rehydration products comprising creatine
US9233099B2 (en) 2012-01-11 2016-01-12 University Of Cincinnati Methods of treating cognitive dysfunction by modulating brain energy metabolism
EP2918177B1 (fr) * 2014-03-11 2019-02-27 Third of Life GmbH Complément alimentaire pour l'optimisation du sommeil
EP2926669B1 (fr) * 2014-04-02 2017-05-24 AlzChem AG Matrice de protéines-créatines ainsi que procédé de fabrication de cette matrice
DE102022114966A1 (de) * 2022-06-14 2023-12-14 Alzchem Trostberg Gmbh Wasserlösliches Kreatin-Agglomerat

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274161B1 (en) * 1996-05-31 2001-08-14 The Howard Foundation Compositions containing creatine in suspension
GB9611356D0 (en) * 1996-05-31 1996-08-07 Howard Alan N Improvements in or relating to compositions containing Creatine, and other ergogenic compounds
US5925378A (en) * 1997-03-31 1999-07-20 Fortress Systems, L.L.C. Method for enhancing delivery and uniformity of concentration of cellular creatine
DE19836450A1 (de) * 1998-08-12 2000-02-17 Sueddeutsche Kalkstickstoff Stabile, Brenztraubensäure (Salze) enthaltende Formulierung für die Tierernährung
US6242491B1 (en) * 1999-06-25 2001-06-05 Rima Kaddurah-Daouk Use of creatine or creatine compounds for skin preservation
DE10017102A1 (de) * 2000-04-06 2001-10-11 Basf Ag Verfahren zur Herstellung von festen Kreatin-Dosierungsformen und dadurch erhältliche Dosierungsformen
US6211407B1 (en) * 2000-05-03 2001-04-03 Pfanstiehl Laboratories, Inc. Dicreatine citrate and tricreatine citrate and method of making same
DE10065478C1 (de) * 2000-12-28 2002-08-29 Sueddeutsche Kalkstickstoff Kreatin/Citronensäure-Verbindung, Verfahren zu ihrer Herstellung und Verwendung

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO03047367A1 *

Also Published As

Publication number Publication date
WO2003047367A1 (fr) 2003-06-12
AU2002350718A1 (en) 2003-06-17
JP2005510579A (ja) 2005-04-21
US20050037069A1 (en) 2005-02-17
DE10159244A1 (de) 2003-06-18

Similar Documents

Publication Publication Date Title
DE602004011790T2 (de) Meldoniumsalze, verfahren zu deren herstellung und auf ihnen basierende pharmazeutische zusammensetzung
DE19653225A1 (de) Kreatin-pyruvate und Verfahren zu deren Herstellung
EP0894083B1 (fr) Creatine pyruvates et leur procede de preparation
EP0185302B1 (fr) Edulcorant, méthode pour sa production et son utilisation
DE19707694A1 (de) Kreatin-ascorbate und Verfahren zu deren Herstellung
EP1450629A1 (fr) Formulation solide et stable contenant au moins un compose de type creatine/acide citrique et au moins un glucide ou leurs hydrates, son procede de production et son utilisation
DE2945790A1 (de) Neutrales kristallines salz einer basischen l-aminosaeure mit l-apfelsaeure und verfahren zu dessen herstellung
DE10065478C1 (de) Kreatin/Citronensäure-Verbindung, Verfahren zu ihrer Herstellung und Verwendung
DE2513931A1 (de) Verfahren zur saccharidpolykondensation
DE19830770C1 (de) Wasserlösliche Zinkpyruvate bzw. deren Hydrate, Verfahren zu ihrer Herstellung und deren Verwendung
DE19859771C1 (de) Wasserlösliche, stabile Brenztraubensäure(-salze)-enthaltende Formulierung
DE10064312C2 (de) Cholinpyruvat-Hydrat, Verfahren zu dessen Herstellung, Cholinpyruvat-Hydrat enthaltende Formulierung sowie deren Verwendung
EP0288747B1 (fr) Produit d'addition du lactate de calcium avec la glycérine, son procédé de préparation et son utilisation
DE938502C (de) Verfahren zur Herstellung einer kolloidalen Eisenzubereitung
DE19935305A1 (de) Feste, stabile Brenztraubensäure/Kohlenhydrat(-Derivat)- Aggregate bzw. deren Hydrate und Verfahren zu ihrer Herstellung
DE1493618A1 (de) Cumarinderivate und ein Verfahren zu ihrer Herstellung
RU2796160C1 (ru) Способ получения желейно-фруктового мармелада функционального назначения
EP0971911A1 (fr) Creatine-ascorbates et mode de preparation
EP0993433B1 (fr) Procede pour la preparation de pyruvates de calcium
DE2134672A1 (de) Wasserloesliches acetylsalicylsaeuresalz, dessen herstellung, zubereitung und anwendung
EP2628397A1 (fr) Compositions édulcorantes renfermant du sucralose
AT277729B (de) Verfahren zur Herstellung einer stabilen, stark lyophilen, entweder festen und lockeren oder pastenartigen Zusammensetzung
DE2909707C2 (de) Fominoben-Theophyllin-Komplex und Verfahren zu seiner Herstellung
DE3343725C2 (fr)
EP1270574A1 (fr) Complexes de caféine à goût amélioré, leur procédé de préparation et leur application

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040604

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: ORTENBURGER, GUENTER

Inventor name: JAEGER, RALF

Inventor name: PISCHEL, IVO

Inventor name: PURPURA, MARTIN

17Q First examination report despatched

Effective date: 20060907

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20071022